Zacks Investment Research on MSN
Coherus Oncology (CHRS) upgraded to buy: Here's what you should know
Coherus Oncology (CHRS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with ...
Kura Oncology (KURA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.22 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results